DEPRESSION 1: Screening and Monitoring in Primary Care Clinics Treating Underserved Patients: Depression as the Sixth Vital Sign
Primary care is the initial access point for the diagnosis and treatment of depression. However, the recognition of major depressive episodes in patients seen in primary care is low. By providing awareness of the incidence, predisposing risk factors of depression and its impact on patient outcomes, primary care providers will attain the foundational competence to identify patients presenting with depression in their settings. By using a screening process that is incorporated into the vital assessment process, screening for depression can easily be adapted into the workflow. Screening for depression has a CPT code that is reimbursable by CMS and commercial insurance.
This training will provide the content and competence for primary care providers to gain confidence in the necessity for incorporating standard measures of screening and identifying patients with depression. Additionally, this program will provide an introduction to the measurement based care approach and describe how it can be integrated into current practices.
Method of Participation
This activity is in a video and synchronized slides format with a closed captions option. A text and slides (PDF) viewing option is also available. References are linked to online resources.
To receive a maximum of 0.75 AMA PRA Category 1 Credit(s)™ you should:
- View the presentations in this enduring material.
- Complete the posttest (you must answer 4 out of 5 questions correctly).
- Complete and submit the CME registration and evaluation forms.
The estimated time to complete this activity, including review of the materials, is 0.75 hours.
Hardware/software requirements: Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.
If you have questions about the participation process, please e-mail the UT Southwestern Medical Center, cmeregistrations@utsouthwestern.edu or phone 214-648-3138.
Accreditation/Credit Designation
The UT Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The UT Southwestern Medical Center designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been designated by UT Southwestern Medical Center for 0.75 hour(s) of education in medical ethics and/or professional responsibility.
Term of Approval
September 2014 through September 2016. Original release date: September 2014.
Peer Review
In July 2014, this continuing medical education online enduring material was reviewed by E. Will Clark, M.D., Instructor, University of Texas Southwestern Medical Center, Dallas, Texas. To ensure the continued scientific relevance of this enduring material, its content will be reviewed again in September 2016.
Disclosures: Nothing to disclose.
Program Director
Robert Rege, MD
Professor of Surgery
Chairman, Office of Continuing Medical Education
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose
Disclaimer
This CME activity is designed for use by healthcare professionals for educational purposes only. Information and opinion offered by the contributors represent their viewpoints. Conclusions drawn by the participant should be derived from careful consideration of all available scientific information. Prescription information and use of medical devices should be undertaken only after confirmation of information by consulting the FDA-approved uses and information.
This CME activity has been planned to be well-balanced and objective in discussion of comparative treatment regimens, and the the activity format allows for the free scientific exchange of ideas. Information and opinions offered by the speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.
Links are provided to other Internet sites solely for the convenience of users. Once you link to another site, you are subject to the site"s terms and conditions of use including copyright and licensing restrictions.
Disclosure
The UT Southwestern Medical Center makes every effort to develop CME activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical EducationStandards for Commercial Support™ the UT Southwestern Medical Center has implemented a mechanism requiring everyone in a position to control the content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships: 1) at the time of the activity or within 12 months prior; and 2) of their spouses/partners.
The UT Southwestern Medical Center does not view the existence of interests or relationships with commercial entities as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.
If at any time during this activity you feel that there has been commercial or promotional bias, please inform us by using the commercial bias comments box in the evaluation form. Please answer the questions about balance in the CME activity evaluation candidly.
The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:
Madhukar H. Trivedi, MD, Presenter
Betty Jo Hay Distinguished Chair in Mental Health
Professor of Psychiatry
Director Comprehensive Center for Depression
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosures:
Consulting: Madhukar H. Trivedi is or has been an advisor/consultant to, Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC/Janssen Pharmaceutica Products, LP/Johnson & Johnson PRD, Lundbeck, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Pfizer Inc., Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd ., Sepracor, SHIRE Development, Sunovion, Takeda, Vivus, and Wyeth-Ayerst Laboratories.
Research Activities: In addition, he has received research support from: Agency for Healthcare Research and Quality (AHRQ), National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Diabetes and Digestive Disorders.
Formal Advisory: Member, Scientific Advisory Board for the Canadian Biomarker Integration Network for Depression (CAN BIND) project (2014). Special Emphasis Panel, ZMH1 ERB – I (04), National Institute of Mental Health (NIMH), Mentored Career Development Award to Build Research Capacity in Global Mental Health, April 9, 2014.
The following individual(s) has/have reported no financial or other relationships with commercial entities whose products/services may relate to the educational content of this activity:
E. Will Clark, MD, Peer Reviewer
Instructor
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose
Ericka Harden-Dews, JD, CCMEP, CME Staff
Associate Director
Office of Continuing Medical & Public Education
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose
Anne N. Perch, MBA, CCMEP, CME Staff
Assistant Vice President
Office of Continuing Medical & Public Education
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose
Deborah Phillips, BSN, RN, MPH, CME Staff
CE Program Coordinator
Office of Continuing Medical & Public Education
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose
Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with the applicable law.
The UT Southwestern Medical Center requires that all contributors disclose an unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products, and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.
Target Audience
This CME activity is designed to meet the educational needs of primary care physicians, nurse practitioners, and physician assistants, particularly those serving underserved and vulnerable populations.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- State three symptoms of major depressive disorder.
- Describe how depression contributes to the overall disease process.
- Identify one tool used to screen patients for depression.
- Describe the prevalence of depression in underserved populations.
Madhukar H. Trivedi, MD, Presenter
Betty Jo Hay Distinguished Chair in Mental Health
Professor of Psychiatry
Director Comprehensive Center for Depression
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosures:
Consulting: Madhukar H. Trivedi is or has been an advisor/consultant to, Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC/Janssen Pharmaceutica Products, LP/Johnson & Johnson PRD, Lundbeck, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Pfizer Inc., Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd ., Sepracor, SHIRE Development, Sunovion, Takeda, Vivus, and Wyeth-Ayerst Laboratories.
Research Activities: In addition, he has received research support from: Agency for Healthcare Research and Quality (AHRQ), National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Diabetes and Digestive Disorders.
Formal Advisory: Member, Scientific Advisory Board for the Canadian Biomarker Integration Network for Depression (CAN BIND) project (2014). Special Emphasis Panel, ZMH1 ERB – I (04), National Institute of Mental Health (NIMH), Mentored Career Development Award to Build Research Capacity in Global Mental Health, April 9, 2014.
Available Credit
- 0.75 AMA
- 0.75 Attendance
- 0.75 Ethics
Price
Required Hardware/software
Hardware/software requirements: Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.